Literature DB >> 14685643

Estradiol and testosterone modulate the anesthetic action of the GABA-A agonist THIP, but not of the neurosteroid 3alpha,5beta-pregnanolone in the rat.

Oscar González-Flores1, Norma Sánchez, Marcos García-Juárez, Francisco Javier Lima-Hernández, Gabriela González-Mariscal, Carlos Beyer.   

Abstract

RATIONALE: As sex steroids modify the number and distribution of brain gamma-aminobutyric acid (GABA)A receptor subunits, we investigated the potential modulation of anesthesia, induced by agents acting on the GABAA receptor, by estrogen and androgen.
OBJECTIVES: To assess possible effects of sex and hormonal condition (i.e., intact vs castrate; estradiol vs testosterone treatment) on the anesthetic effect of a GABAA agonist, THIP (4,5,6,7-tetrahydroisoxazolo[5,4,-c]pyridin-3-ol hydrochloride), and an allosteric modulator of the GABAA receptor: 3alpha-hydroxy-5beta-pregnan-20-one (epipregnanolone).
METHODS: The potencies of THIP and epipregnanolone for inducing loss of the righting response were compared between: (a) female and male rats; (b) intact and castrated animals of each sex; (c) untreated castrates and castrates given estradiol or testosterone.
RESULTS: Sex and endocrine condition influenced sensitivity to i.v. THIP for the induction of anesthesia. ED50 values were: gonadectomized females, 80 mg/kg>intact males, 50 mg/kg>proestrous females, 35 mg/kg>gonadectomized males, 28 mg/kg. Estradiol benzoate (EB; 3 microg/day for 5 days) significantly increased THIP sensitivity in gonadectomized females: THIP+EB: ED50=26 mg/kg vs THIP+sesame oil: ED50=94 mg/kg, while testosterone propionate (TP; 10 mg injected 24 h before THIP) decreased THIP sensitivity in orchidectomized males when compared with vehicle-injected animals (ED50=72 mg/kg vs 22 mg/kg, respectively).
CONCLUSIONS: Results suggest that estrogen increases the density or availability of GABAA receptor subtypes on which THIP acts, while testosterone exerts the opposite effect. Neither sex nor gonadal condition influenced the anesthetic action of epipregnanolone as a similar potency was found in intact and in gonadectomized males and females.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14685643     DOI: 10.1007/s00213-003-1649-x

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  65 in total

1.  The control of progesterone secretion during the estrous cycle and early pseudopregnancy in the rat: prolactin, gonadotropin and steroid levels associated with rescue of the corpus luteum of pseudopregnancy.

Authors:  M S Smith; M E Freeman; J D Neill
Journal:  Endocrinology       Date:  1975-01       Impact factor: 4.736

2.  Testosterone rapidly reduces anxiety in male house mice (Mus musculus).

Authors:  Jeremy L Aikey; John G Nyby; David M Anmuth; Peter J James
Journal:  Horm Behav       Date:  2002-12       Impact factor: 3.587

Review 3.  Estrogen regulation of GABA transmission in rat preoptic area.

Authors:  A E Herbison
Journal:  Brain Res Bull       Date:  1997       Impact factor: 4.077

4.  Steroid hormone metabolites are barbiturate-like modulators of the GABA receptor.

Authors:  M D Majewska; N L Harrison; R D Schwartz; J L Barker; S M Paul
Journal:  Science       Date:  1986-05-23       Impact factor: 47.728

Review 5.  Neurosteroids and GABAA receptor function.

Authors:  J J Lambert; D Belelli; C Hill-Venning; J A Peters
Journal:  Trends Pharmacol Sci       Date:  1995-09       Impact factor: 14.819

6.  Estrogen modulation of the gamma-aminobutyric acid receptor complex in the central nervous system of rat.

Authors:  J Perez; I Zucchi; A Maggi
Journal:  J Pharmacol Exp Ther       Date:  1988-03       Impact factor: 4.030

7.  Regulation of high-affinity GABAA receptors in the dorsal hippocampus by estradiol and progesterone.

Authors:  M Schumacher; H Coirini; B S McEwen
Journal:  Brain Res       Date:  1989-05-15       Impact factor: 3.252

8.  The locomotor-reducing effects of GABAergic drugs do not depend on the GABAA receptor.

Authors:  A Agmo; M Giordano
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

9.  Perispinal progestins enhance the antinociceptive effects of muscimol in the rat.

Authors:  M Caba; G González-Mariscal; C Beyer
Journal:  Pharmacol Biochem Behav       Date:  1994-01       Impact factor: 3.533

10.  Analgesic properties of the GABA-mimetic THIP.

Authors:  R C Hill; R Maurer; H H Buescher; D Roemer
Journal:  Eur J Pharmacol       Date:  1981-01-16       Impact factor: 4.432

View more
  5 in total

1.  EEG power spectra response to a 4-h phase advance and gaboxadol treatment in 822 men and women.

Authors:  Junshui Ma; Derk-Jan Dijk; Vladimir Svetnik; Yevgen Tymofyeyev; Shubhankar Ray; James K Walsh; Steve Deacon
Journal:  J Clin Sleep Med       Date:  2011-10-15       Impact factor: 4.062

2.  Reduced Chrna7 expression in mice is associated with decreases in hippocampal markers of inhibitory function: implications for neuropsychiatric diseases.

Authors:  C E Adams; J C Yonchek; K M Schulz; S L Graw; J Stitzel; P U Teschke; K E Stevens
Journal:  Neuroscience       Date:  2012-01-25       Impact factor: 3.590

3.  Effects of gaboxadol on the expression of cocaine sensitization in rats.

Authors:  Nora Siegal Silverman; Susanna Popp; Vincent Vialou; Konstantin Astafurov; Eric J Nestler; Diana Dow-Edwards
Journal:  Exp Clin Psychopharmacol       Date:  2016-02-22       Impact factor: 3.157

4.  Sex differences in GABAergic neurotransmission to rat DMV neurons.

Authors:  Yanyan Jiang; Tanja Babic; R Alberto Travagli
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2019-08-08       Impact factor: 4.052

5.  Effect of gaboxadol on patient-reported measures of sleep and waking function in patients with Primary Insomnia: results from two randomized, controlled, 3-month studies.

Authors:  Thomas Roth; Christopher Lines; Kristel Vandormael; Paulette Ceesay; Donald Anderson; Duane Snavely
Journal:  J Clin Sleep Med       Date:  2010-02-15       Impact factor: 4.062

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.